Catalyst
Monitor for regulatory submissions and potential label expansions for TALZENNA and XTANDI based on these trial results.
Date
June 16, 2026
Phase
N/A
Status
watch
Signal score
8.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.